2025 Q4 -tulosraportti
18 päivää sitten
‧1 t 12 min
7,95 DKK/osake
Irtoamispäivä 27.3.
3,79%Tuotto/v
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
2 071 292
Myynti
Määrä
2 451 087
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 429 | - | - | ||
| 3 790 | - | - | ||
| 100 | - | - | ||
| 100 | - | - | ||
| 1 | - | - |
Ylin
310,75VWAP
Alin
298,5VaihtoMäärä
1 720,1 5 688 416
VWAP
Ylin
310,75Alin
298,5VaihtoMäärä
1 720,1 5 688 416
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 6.8.2025 | ||
2025 Q1 -tulosraportti 7.5.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·1 t sittenExperiences with Novo Nordisk – Depot 2 Everyone must make the decisions that suit their own risk profile. Personally, I have had good experiences with Novo Nordisk for about eight years in my depot 2. I bought shares for around 316 kr. each, and the share was later split, so my acquisition price is now 158 kr. per share. New purchases in Depot 1 In my depot 1, over the past eight months, I have bought Novo Nordisk shares at prices between approximately 550 kr. and 265 kr. The average acquisition price for this depot is approximately 318 kr. Reflections on risk and advice I sleep soundly at night, even though no stock is without risk, I am aware that I have been very lucky with Novo Nordisk. My point is that no one can give good advice without knowing others' circumstances and risk profile. I can choose to sell or rebalance when the money suits – Or not to Or use Novo Nordisk as a supplement to my pension if I live longer than my self-pension runs Conclusion No matter what happens, I get my liver pâté sandwich with tomato. The most important thing is to invest on your own terms and be able to sleep soundly at night.
·4 t sittenThere are two types of people on Nordnet. 1. Those who can see the long-term potential in Novo 2. Those who bought the stock at price 1000, sold it in a panic at price 290, and now dedicate their lives to writing sour and negative comments. You know who you are. 👊
·2 t sittenHow do you actually think it's going yourself? Long-term potential, yes, all stocks certainly have that. But please give an update on how well it has gone since you claimed that Novo would never go below 400 again! Everyone who has listened to your fantasies has lost capital and will probably never earn it back. Almost regardless of when one has sold off Novo in the last 2 years, they are better off than those who have held or just bought in within the last 6 months. Investing is also about thinking realistically and logically instead of just sitting on your hands and waiting for prescription numbers next Friday, because then Novo will go to the moon. Cagrisema ÷20%, tolduro ÷20%, financial report ÷20% and Pillen, Novo's golden pig 0%.
·5 t sitten📈 Short investment analysis: Why Novo Nordisk can rise in 2026 Investment case (bull): Novo Nordisk continues to have a strong structural growth story within obesity and diabetes. After share price declines and lower expectations, 2026 could be the year the stock is re-rated upwards. 🔑 Key drivers • Product growth: Wegovy and Ozempic are still expected to drive high revenue, supported by new doses, indications, and broader geographical reach. • Structural demand: Obesity and type 2 diabetes are growing globally – a market with many years of growth ahead. • Valuation: The stock trades lower than historical multiples after negative sentiment, which provides potential for multiple expansion upon positive news. • Capital discipline: Share buybacks and strong cash flow support earnings per share. ⚠️ Risks • Competition: Pressure from, among others, Eli Lilly. • Price regulation: Especially in the USA. • Execution risk: Production capacity and delivery reliability. 🧠 Conclusion If Novo delivers stable growth and just small positive surprises in 2026, the stock could react significantly upwards, as much negativity already seems priced into the share price. 📈
·6 t sittenI hope there is an investor who stands up and asks for less dividend and more buybacks. The stock has not been so cheap on P/E in living memory, so now is the time to scoop up shares. The same applies to Pandora, by the way.
·6 t sitten · MuokattuYou just do that. You don't need to rush. Pandora will be cheaper tomorrow. I'm sticking to American IT companies and defense stocks. Those consumer stocks are having a tough time and will continue to do so. And stocks that are dependent on metals have bigger problems ahead of them.
7 t sitten · Muokattu7 t sitten · MuokattuThe weight loss drugs are not unique to Novo..., the competition operates at lower costs. Novo Nordisk as many Scandinavian companies lack the at all cost attitude to dominate the market. True Novo has a solid product, the company seems healthy - it's sad. I am thinking of selling as soon as I get from the current -17% to -7%. Moving money to more stable investments. (I had a hypothesis that it would go to 400-415 (it did, had a good guesstimate), then decided to wait a bit and then it dropped, so a classical investment human mistake on my part, never again.) Now my new hypothesis: will fluctuate, it might even go up to 360-400, but 450 is not feasible within 2-5 years. Of course it might go downhill, now I look at this stock in more negative light, so looking for a comfortable opportunity to leave 350, 360, 375, (and above is my comfy buy out)
·5 t sittenI think that weight loss medication is a small part of Novo's revenue and profit currently, but things need to speed up so momentum and trust can be maintained for the future.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
18 päivää sitten
‧1 t 12 min
7,95 DKK/osake
Irtoamispäivä 27.3.
3,79%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 t sittenExperiences with Novo Nordisk – Depot 2 Everyone must make the decisions that suit their own risk profile. Personally, I have had good experiences with Novo Nordisk for about eight years in my depot 2. I bought shares for around 316 kr. each, and the share was later split, so my acquisition price is now 158 kr. per share. New purchases in Depot 1 In my depot 1, over the past eight months, I have bought Novo Nordisk shares at prices between approximately 550 kr. and 265 kr. The average acquisition price for this depot is approximately 318 kr. Reflections on risk and advice I sleep soundly at night, even though no stock is without risk, I am aware that I have been very lucky with Novo Nordisk. My point is that no one can give good advice without knowing others' circumstances and risk profile. I can choose to sell or rebalance when the money suits – Or not to Or use Novo Nordisk as a supplement to my pension if I live longer than my self-pension runs Conclusion No matter what happens, I get my liver pâté sandwich with tomato. The most important thing is to invest on your own terms and be able to sleep soundly at night.
- ·4 t sittenThere are two types of people on Nordnet. 1. Those who can see the long-term potential in Novo 2. Those who bought the stock at price 1000, sold it in a panic at price 290, and now dedicate their lives to writing sour and negative comments. You know who you are. 👊·2 t sittenHow do you actually think it's going yourself? Long-term potential, yes, all stocks certainly have that. But please give an update on how well it has gone since you claimed that Novo would never go below 400 again! Everyone who has listened to your fantasies has lost capital and will probably never earn it back. Almost regardless of when one has sold off Novo in the last 2 years, they are better off than those who have held or just bought in within the last 6 months. Investing is also about thinking realistically and logically instead of just sitting on your hands and waiting for prescription numbers next Friday, because then Novo will go to the moon. Cagrisema ÷20%, tolduro ÷20%, financial report ÷20% and Pillen, Novo's golden pig 0%.
- ·5 t sitten📈 Short investment analysis: Why Novo Nordisk can rise in 2026 Investment case (bull): Novo Nordisk continues to have a strong structural growth story within obesity and diabetes. After share price declines and lower expectations, 2026 could be the year the stock is re-rated upwards. 🔑 Key drivers • Product growth: Wegovy and Ozempic are still expected to drive high revenue, supported by new doses, indications, and broader geographical reach. • Structural demand: Obesity and type 2 diabetes are growing globally – a market with many years of growth ahead. • Valuation: The stock trades lower than historical multiples after negative sentiment, which provides potential for multiple expansion upon positive news. • Capital discipline: Share buybacks and strong cash flow support earnings per share. ⚠️ Risks • Competition: Pressure from, among others, Eli Lilly. • Price regulation: Especially in the USA. • Execution risk: Production capacity and delivery reliability. 🧠 Conclusion If Novo delivers stable growth and just small positive surprises in 2026, the stock could react significantly upwards, as much negativity already seems priced into the share price. 📈
- ·6 t sittenI hope there is an investor who stands up and asks for less dividend and more buybacks. The stock has not been so cheap on P/E in living memory, so now is the time to scoop up shares. The same applies to Pandora, by the way.·6 t sitten · MuokattuYou just do that. You don't need to rush. Pandora will be cheaper tomorrow. I'm sticking to American IT companies and defense stocks. Those consumer stocks are having a tough time and will continue to do so. And stocks that are dependent on metals have bigger problems ahead of them.
- 7 t sitten · Muokattu7 t sitten · MuokattuThe weight loss drugs are not unique to Novo..., the competition operates at lower costs. Novo Nordisk as many Scandinavian companies lack the at all cost attitude to dominate the market. True Novo has a solid product, the company seems healthy - it's sad. I am thinking of selling as soon as I get from the current -17% to -7%. Moving money to more stable investments. (I had a hypothesis that it would go to 400-415 (it did, had a good guesstimate), then decided to wait a bit and then it dropped, so a classical investment human mistake on my part, never again.) Now my new hypothesis: will fluctuate, it might even go up to 360-400, but 450 is not feasible within 2-5 years. Of course it might go downhill, now I look at this stock in more negative light, so looking for a comfortable opportunity to leave 350, 360, 375, (and above is my comfy buy out)·5 t sittenI think that weight loss medication is a small part of Novo's revenue and profit currently, but things need to speed up so momentum and trust can be maintained for the future.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
2 071 292
Myynti
Määrä
2 451 087
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 429 | - | - | ||
| 3 790 | - | - | ||
| 100 | - | - | ||
| 100 | - | - | ||
| 1 | - | - |
Ylin
310,75VWAP
Alin
298,5VaihtoMäärä
1 720,1 5 688 416
VWAP
Ylin
310,75Alin
298,5VaihtoMäärä
1 720,1 5 688 416
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 6.8.2025 | ||
2025 Q1 -tulosraportti 7.5.2025 |
2025 Q4 -tulosraportti
18 päivää sitten
‧1 t 12 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 6.8.2025 | ||
2025 Q1 -tulosraportti 7.5.2025 |
7,95 DKK/osake
Irtoamispäivä 27.3.
3,79%Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 t sittenExperiences with Novo Nordisk – Depot 2 Everyone must make the decisions that suit their own risk profile. Personally, I have had good experiences with Novo Nordisk for about eight years in my depot 2. I bought shares for around 316 kr. each, and the share was later split, so my acquisition price is now 158 kr. per share. New purchases in Depot 1 In my depot 1, over the past eight months, I have bought Novo Nordisk shares at prices between approximately 550 kr. and 265 kr. The average acquisition price for this depot is approximately 318 kr. Reflections on risk and advice I sleep soundly at night, even though no stock is without risk, I am aware that I have been very lucky with Novo Nordisk. My point is that no one can give good advice without knowing others' circumstances and risk profile. I can choose to sell or rebalance when the money suits – Or not to Or use Novo Nordisk as a supplement to my pension if I live longer than my self-pension runs Conclusion No matter what happens, I get my liver pâté sandwich with tomato. The most important thing is to invest on your own terms and be able to sleep soundly at night.
- ·4 t sittenThere are two types of people on Nordnet. 1. Those who can see the long-term potential in Novo 2. Those who bought the stock at price 1000, sold it in a panic at price 290, and now dedicate their lives to writing sour and negative comments. You know who you are. 👊·2 t sittenHow do you actually think it's going yourself? Long-term potential, yes, all stocks certainly have that. But please give an update on how well it has gone since you claimed that Novo would never go below 400 again! Everyone who has listened to your fantasies has lost capital and will probably never earn it back. Almost regardless of when one has sold off Novo in the last 2 years, they are better off than those who have held or just bought in within the last 6 months. Investing is also about thinking realistically and logically instead of just sitting on your hands and waiting for prescription numbers next Friday, because then Novo will go to the moon. Cagrisema ÷20%, tolduro ÷20%, financial report ÷20% and Pillen, Novo's golden pig 0%.
- ·5 t sitten📈 Short investment analysis: Why Novo Nordisk can rise in 2026 Investment case (bull): Novo Nordisk continues to have a strong structural growth story within obesity and diabetes. After share price declines and lower expectations, 2026 could be the year the stock is re-rated upwards. 🔑 Key drivers • Product growth: Wegovy and Ozempic are still expected to drive high revenue, supported by new doses, indications, and broader geographical reach. • Structural demand: Obesity and type 2 diabetes are growing globally – a market with many years of growth ahead. • Valuation: The stock trades lower than historical multiples after negative sentiment, which provides potential for multiple expansion upon positive news. • Capital discipline: Share buybacks and strong cash flow support earnings per share. ⚠️ Risks • Competition: Pressure from, among others, Eli Lilly. • Price regulation: Especially in the USA. • Execution risk: Production capacity and delivery reliability. 🧠 Conclusion If Novo delivers stable growth and just small positive surprises in 2026, the stock could react significantly upwards, as much negativity already seems priced into the share price. 📈
- ·6 t sittenI hope there is an investor who stands up and asks for less dividend and more buybacks. The stock has not been so cheap on P/E in living memory, so now is the time to scoop up shares. The same applies to Pandora, by the way.·6 t sitten · MuokattuYou just do that. You don't need to rush. Pandora will be cheaper tomorrow. I'm sticking to American IT companies and defense stocks. Those consumer stocks are having a tough time and will continue to do so. And stocks that are dependent on metals have bigger problems ahead of them.
- 7 t sitten · Muokattu7 t sitten · MuokattuThe weight loss drugs are not unique to Novo..., the competition operates at lower costs. Novo Nordisk as many Scandinavian companies lack the at all cost attitude to dominate the market. True Novo has a solid product, the company seems healthy - it's sad. I am thinking of selling as soon as I get from the current -17% to -7%. Moving money to more stable investments. (I had a hypothesis that it would go to 400-415 (it did, had a good guesstimate), then decided to wait a bit and then it dropped, so a classical investment human mistake on my part, never again.) Now my new hypothesis: will fluctuate, it might even go up to 360-400, but 450 is not feasible within 2-5 years. Of course it might go downhill, now I look at this stock in more negative light, so looking for a comfortable opportunity to leave 350, 360, 375, (and above is my comfy buy out)·5 t sittenI think that weight loss medication is a small part of Novo's revenue and profit currently, but things need to speed up so momentum and trust can be maintained for the future.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
2 071 292
Myynti
Määrä
2 451 087
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 429 | - | - | ||
| 3 790 | - | - | ||
| 100 | - | - | ||
| 100 | - | - | ||
| 1 | - | - |
Ylin
310,75VWAP
Alin
298,5VaihtoMäärä
1 720,1 5 688 416
VWAP
Ylin
310,75Alin
298,5VaihtoMäärä
1 720,1 5 688 416
Välittäjätilasto
Dataa ei löytynyt